Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM.

Sci Transl Med. 2016 May 11;8(338):338ra66. doi: 10.1126/scitranslmed.aaf2362.

2.

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL.

Brain. 2016 Aug;139(Pt 8):2249-60. doi: 10.1093/brain/aww139. Epub 2016 Jun 10.

3.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

4.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
5.

Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.

Chiaravalloti A, Barbagallo G, Ricci M, Martorana A, Ursini F, Sannino P, Karalis G, Schillaci O.

Brain Res. 2018 Jan 1;1678:116-122. doi: 10.1016/j.brainres.2017.10.016. Epub 2017 Oct 21.

PMID:
29066367
6.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
7.

PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.

Koychev I, Gunn RN, Firouzian A, Lawson J, Zamboni G, Ridha B, Sahakian BJ, Rowe JB, Thomas A, Rochester L, Ffytche D, Howard R, Zetterberg H, MacKay C, Lovestone S; Deep and Frequent Phenotyping study team (.

J Alzheimers Dis. 2017;60(1):283-293. doi: 10.3233/JAD-170129.

8.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

9.

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.

Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.

10.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

11.

Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.

Schroeter ML, Tiepolt S, Marschhauser A, Thöne-Otto A, Hoffmann KT, Barthel H, Obrig H, Sabri O.

BMC Neurol. 2015 Aug 26;15:152. doi: 10.1186/s12883-015-0410-5.

12.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM.

Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.

13.

[Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].

Watanabe H.

Yakugaku Zasshi. 2017;137(11):1361-1365. doi: 10.1248/yakushi.17-00156. Review. Japanese.

14.

Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.

Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Aug;11(8):986-93. doi: 10.1016/j.jalz.2015.03.002. Epub 2015 Apr 24.

15.

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.

J Alzheimers Dis. 2015;45(4):1077-88. doi: 10.3233/JAD-142952.

PMID:
25649653
16.

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.

Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, Jackson JD, Mormino EC, Rentz DM, Sperling RA, Johnson KA, Amariglio RE.

JAMA Neurol. 2017 Dec 1;74(12):1455-1463. doi: 10.1001/jamaneurol.2017.2216.

17.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

18.

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

19.

Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.

Weise D, Tiepolt S, Awissus C, Hoffmann KT, Lobsien D, Kaiser T, Barthel H, Sabri O, Gertz HJ.

J Alzheimers Dis. 2015;48(2):425-32. doi: 10.3233/JAD-150229.

PMID:
26402006
20.

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.

Voyle N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ, Dobson RJ, Kiddle SJ; EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.

Supplemental Content

Support Center